SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals, which recently got listed on BSE and NSE on April 2, 2026, has informed exchanges that it will not meet the April 23, 2026 deadline for submitting its quarterly financial results for the period ended December 31, 2025. The company is seeking an extension until May 15, 2026. The delay is attributed to the ongoing audit of its newly acquired step-down subsidiary Noumed Pharmaceuticals PTY Limited (Australia), held through wholly owned subsidiary Sai Singapore Pte. Ltd. The Australian entity's financial year ends December 31, 2025, and its audited financials are expected only by the first week of May 2026. After receiving those numbers, Sai Parenterals will need additional time to compile both standalone and consolidated results and obtain a limited review from its statutory auditors. The full-year FY26 audited results are expected by May 30, 2026.
This is a procedural delay announcement and not a results filing itself. For shareholders, it means actual financial numbers are still pending, so there is no fresh earnings data to act on yet. The stated reason — waiting on a foreign subsidiary's audit — is a common compliance issue for newly listed companies with international operations, but investors should track the May 15 deadline to see whether the results arrive on time.